Skip to content
Clinical Trials – home
Not recruiting

Study of Durvalumab and Regorafenib for Patients with Stage IV Colorectal Cancer with No Evidence of Disease

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for patients with stage IV colorectal cancer who currently show no evidence of the disease. The study will explore the effects of two medications: durvalumab, also known by its code name MEDI4736, and regorafenib, which is referred to as BAY 734506. Durvalumab is given as a solution for infusion, meaning it is administered directly into the bloodstream through a vein, while regorafenib is taken orally as a film-coated tablet.

The purpose of this study is to evaluate how well these treatments work in preventing the return of cancer in patients who have already undergone treatment and currently have no detectable disease. Participants will be randomly assigned to receive either the combination of durvalumab and regorafenib or no additional treatment. The study will last for up to 12 months, during which time the health of the participants will be closely monitored.

The main goal is to determine if the combination of these medications can help patients remain free of cancer for a longer period. The study will also look at the overall survival of participants, any side effects they may experience, and how well they adhere to the treatment plan. This research aims to provide valuable insights into improving outcomes for patients with advanced colorectal cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed. Participants must be at least 18 years old and have a confirmed diagnosis of colorectal adenocarcinoma. It is essential to be in a state of no evidence of disease (NED) after completing treatments for stage IV colorectal cancer.

    The NED state is verified through imaging tests such as a CT scan, PET scan, or MRI scan. Randomization into the study must occur within 10 weeks of achieving the NED state.

  2. Step 2

    Randomization

    Participants are randomly assigned to one of two groups: one receiving the experimental treatment and the other serving as an untreated control group.

    Those who have received additional therapy after local treatment or achieved a complete response with systemic therapies must be randomized within 4 weeks of their last chemotherapy cycle.

  3. Step 3

    Treatment phase

    Participants in the treatment group receive two medications: regorafenib and durvalumab.

    Regorafenib is administered orally in the form of a film-coated tablet. The dosage and frequency are determined by the study protocol.

    Durvalumab is given as an intravenous infusion, which means it is delivered directly into a vein. The concentration is 50 mg/mL, and the specific dosage and schedule are outlined in the study protocol.

  4. Step 4

    Monitoring and follow-up

    Participants are regularly monitored to assess disease-free survival (DFS), which is the main goal of the study. This involves periodic health assessments and imaging tests.

    Secondary outcomes include 18-month DFS, overall survival, and monitoring for any adverse events or side effects from the treatment.

  5. Step 5

    Completion of the study

    The study is expected to conclude by December 31, 2029. Participants will be informed of the study's findings and any implications for their health.

    Throughout the study, compliance with the treatment protocol is evaluated to ensure the accuracy and reliability of the results.

Who can join the trial?

5 criteria

  • Must be 18 years or older.
  • Must have a confirmed diagnosis of colorectal adenocarcinoma, which is a type of cancer that starts in the colon or rectum.
  • Must have no evidence of disease (NED) after completing treatments for stage IV colorectal cancer. This means there are no signs of cancer after treatments like surgery, radiofrequency ablation (RFA), radiation therapy (RT), or chemotherapy.
  • The NED state must be confirmed by a CT scan, PET scan, or MRI scan. These are imaging tests that help doctors see inside the body.
  • Must be able to start the study within 10 weeks after reaching the NED state. If you had additional therapy after local treatments or achieved a complete response with systemic therapies, you must start the study within 4 weeks after the last chemotherapy cycle.

Who cannot join the trial?

1 criterion

  • Patients who do not have Stage IV colorectal cancer with no evidence of disease (NED) cannot participate.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Durvalumab

    is a type of medication known as an immunotherapy. It works by helping your immune system recognize and attack cancer cells. In this trial, durvalumab is used to try to prevent the return of colorectal cancer after it has been treated and there is no evidence of disease.

  • Regorafenib

    is a medication that targets specific proteins in cancer cells, which can help stop the cancer from growing and spreading. It is used in this trial to see if it can help keep colorectal cancer from coming back after treatment.

What is already known about the treatment

  • Durvalumab

    Durvalumab is administered as an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its effectiveness in treating stage IV colorectal cancer patients who show no evidence of disease. The main therapeutic indication for durvalumab in this trial is to improve disease-free survival, which means helping patients stay free of cancer for longer periods. At the molecular level, durvalumab works by blocking a protein called PD-L1, which helps the immune system recognize and attack cancer cells. It is classified as an immunotherapy drug, specifically a checkpoint inhibitor, which helps the body's immune system fight cancer.

  • Regorafenib

    Regorafenib is taken orally in the form of a tablet, which means it is swallowed and absorbed through the digestive system. It is being tested in clinical trials for its potential to help stage IV colorectal cancer patients who have no evidence of disease. The main therapeutic goal of regorafenib in this context is to extend the time patients remain free of cancer. Regorafenib works by inhibiting multiple proteins involved in cancer cell growth and blood vessel formation, effectively slowing down or stopping the growth of cancer cells. It is classified as a multi-kinase inhibitor, a type of targeted therapy that interferes with specific pathways in cancer cells.

Investigated diseases

Colorectal Cancer – Colorectal cancer is a type of cancer that begins in the colon or rectum, parts of the large intestine. It often starts as small, noncancerous clumps of cells called polyps that form on the inside of the colon or rectum. Over time, some of these polyps can become cancerous. As the disease progresses, it can invade and damage nearby tissues and organs. In advanced stages, cancer cells may spread to other parts of the body through the blood and lymph systems. The progression of the disease can vary, with some cases remaining localized while others spread more aggressively.
Trial detailsLast updated 30 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518217-26-00Protocol codeVIVAEstimated enrolment182 patientsSponsorIRCCS Ospedale Policlinico San Martino

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.